Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
Iterum Therapeutics (Nasdaq: ITRM), a developer of next-generation oral and IV antibiotics, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before U.S. markets open.
The company will host a conference call at 8:30 a.m. ET on the same day, where management will discuss financial results and provide a business update. Investors can access the call via phone using the numbers 833-470-1428 (domestic) or 404-975-4839 (international) with Access Code 740801. A webcast will be available on the company's investor relations website.
Iterum Therapeutics (Nasdaq: ITRM), un'azienda specializzata nello sviluppo di antibiotici orali e endovenosi di nuova generazione, ha programmato la comunicazione dei risultati finanziari del secondo trimestre 2025 per il 5 agosto 2025, prima dell'apertura dei mercati statunitensi.
La società terrà una conference call alle 8:30 a.m. ET dello stesso giorno, durante la quale il management discuterà i risultati finanziari e fornirà un aggiornamento sull’andamento aziendale. Gli investitori potranno partecipare alla chiamata telefonando ai numeri 833-470-1428 (nazionale) o 404-975-4839 (internazionale) con il codice di accesso 740801. Una trasmissione in webcast sarà disponibile sul sito web delle relazioni con gli investitori della società.
Iterum Therapeutics (Nasdaq: ITRM), una empresa desarrolladora de antibióticos orales e intravenosos de próxima generación, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el 5 de agosto de 2025, antes de la apertura de los mercados en EE.UU.
La compañía realizará una llamada conferencia a las 8:30 a.m. ET ese mismo día, donde la dirección discutirá los resultados financieros y ofrecerá una actualización del negocio. Los inversionistas podrán acceder a la llamada telefónicamente usando los números 833-470-1428 (nacional) o 404-975-4839 (internacional) con el código de acceso 740801. También habrá una transmisión en webcast disponible en el sitio web de relaciones con inversionistas de la empresa.
Iterum Therapeutics (나스닥: ITRM)는 차세대 경구 및 정맥 주사 항생제 개발업체로서, 2025년 2분기 재무 실적 발표를 2025년 8월 5일 미국 증시 개장 전에 예정하고 있습니다.
회사는 같은 날 동부 표준시 오전 8시 30분에 컨퍼런스 콜을 개최하여 경영진이 재무 결과를 논의하고 사업 현황을 업데이트할 예정입니다. 투자자들은 국내 전화번호 833-470-1428 또는 국제 전화번호 404-975-4839에 접속 코드 740801을 입력하여 전화로 참여할 수 있습니다. 회사의 투자자 관계 웹사이트에서 웹캐스트도 제공됩니다.
Iterum Therapeutics (Nasdaq : ITRM), développeur d'antibiotiques oraux et intraveineux de nouvelle génération, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 pour le 5 août 2025, avant l'ouverture des marchés américains.
La société tiendra une conférence téléphonique à 8h30 ET le même jour, au cours de laquelle la direction discutera des résultats financiers et fournira une mise à jour commerciale. Les investisseurs pourront accéder à l'appel par téléphone en composant les numéros 833-470-1428 (domestique) ou 404-975-4839 (international) avec le code d'accès 740801. Un webcast sera disponible sur le site des relations investisseurs de la société.
Iterum Therapeutics (Nasdaq: ITRM), ein Entwickler von oralen und intravenösen Antibiotika der nächsten Generation, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 5. August 2025 vor Öffnung der US-Märkte angekündigt.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz abhalten, in der das Management die Finanzergebnisse besprechen und ein Unternehmensupdate geben wird. Investoren können über die Telefonnummern 833-470-1428 (inländisch) oder 404-975-4839 (international) mit dem Zugangscode 740801 teilnehmen. Ein Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
DUBLIN, Ireland and CHICAGO, July 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, August 5, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 740801. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/143945533. The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
When will Iterum Therapeutics (ITRM) report Q2 2025 earnings?
How can investors join Iterum Therapeutics' Q2 2025 earnings call?
What time is Iterum Therapeutics' Q2 2025 earnings call?
Where can I find Iterum Therapeutics' Q2 2025 earnings webcast?
